Analyses of the toxic properties of recombinant human Cyclophilin A in mice

• Main Authors: Anastasiya Kalinina, Mariya Zamkova, Elena Antoshina, Lubov Trukhanova, Tatyana Gorkova, Dmitriy Kazansky, Ludmila Khromykh
• Format: Article
• Language: English
• Published: Taylor & Francis Group 2019-01-01
• Series: Journal of Immunotoxicology
• Subjects: cyclophilin a; acute toxicity; kidney injury; acute phase proteins
• Online Access: http://dx.doi.org/10.1080/1547691X.2019.1665597

Cyclophilin A (CypA), an 18 kDa multi-functional protein with cis–trans isomerase activity, is both a ligand for cyclosporine A and a proinflammatory factor. CypA is also a chemoattractant for hemopoietic stem cells and progenitors of different lineages, and can mediate regenerative processes in an organism. Accumulated experimental data have suggested there are practical applications for this protein in the treatment of several diseases (i.e. neutralization of cyclosporine A side effects, etc.). However, the range of CypA safe doses as well as its toxic effects remain unknown. The study here investigated the acute toxicity of a single intraperitoneal (IP) or subcutaneous (SC) dosing of recombinant human CypA (rhCypA) in both female and male mice and its effect on gene expression of acute phase proteins (APP) in the female mice after IP treatment. The results showed that toxicity of rhCypA was most evident in female and male mice dosed IP with 750 mg/kg, and manifested as kidney injury and increased granulocyte/lymphocyte ratios in the blood. Enhanced expression of Sаа1 and Sаа2 genes was induced with doses of 0.1–2 mg/mouse of rhCypA. Injection of the maximal dose (750 mg/kg) significantly stimulated expression of all the APP genes studied.